Temporary cessation of ibrutinib results in reduced grade 3‐4 infections and durable remissions—Interim analysis of an on‐off‐repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia

Autor: Jeanette Lundin, Tom A. Mulder, Magdalena Kättström, Tove Wästerlid, Anders Uddevik, Håkan Mellstedt, Kia Heimersson, Lotta Hansson, Marzia Palma, Anders Österborg
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: eJHaem, Vol 2, Iss 3, Pp 525-529 (2021)
Druh dokumentu: article
ISSN: 2688-6146
73744425
DOI: 10.1002/jha2.261
Popis: Abstract Ibrutinib is used continuously in CLL. This phase 1b/2 study interim analysis explored on‐off‐repeat dosing to reduce toxicity. After 12 months, 16/22 patients (73%) remained in first off‐phase irrespective if initial CR/PR or TP53 aberration. Grade 3‐4 infections were reduced from 55% to 5% during a similarly long off‐phase (P
Databáze: Directory of Open Access Journals
Externí odkaz: